National Institutes of Health Grants $7.7 Million for HIV Research

Developing a cure for HIV has been complicated for multiple reasons, the most prominent being viral reservoirs. When patients adhere to antiretroviral therapy, the virus goes through a period of latency, but can re-emerge from these hidden reservoirs in cases of drug-resistance or non-adherence.
 
Countless studies have been dedicated to understanding how and why HIV does this, according to a press release from UCLA.
 
“It’s the resurrection of virus that you couldn’t see in the body before,” Jerome Zack, director, UCLA Center for AIDS Research, said in the release.
 
The National Institute of Allergy and Infectious Diseases recently granted Dr Zack and his team a $7.7 million grant to fund 3 projects that address HIV viral reservoirs, according to the release.
 
The projects will determine factors that contribute to both suppression and re-emergence of HIV. Additionally, the studies will investigate whether a strengthened immune system—either by genetic modification or vaccine—could control HIV rebound.
 
The researchers will use mice to determine how the virus develops and how it affects the body, according to the release.
 
“You cannot infect mice with HIV,” Dr Zack said. “The only animals that can be infected with HIV are humans and related species including chimpanzees and gorillas, and we’re not using these as models. But if you take a mouse that doesn’t have its own immune system, you can transplant elements of the human immune system into the mice, they will engraft, and then you can infect those human components with HIV.”
 
Dr Zack said that scientists have used this type of model to study HIV for nearly 3 decades.
 
“We’ve optimized these models so we can now test rebound, which is probably the key thing that is forcing people to remain on HIV drugs, known as antiretroviral therapy, for life,” Dr Zack said in the release.
 
The overall goal of the new studies is to create a way for HIV-positive patients to discontinue treatment without the risk of viral rebound, thus creating the HIV cure that has eluded researchers so far.
 
The team has already seen promising results, according to the release. They previously published results from a study about a “kick and kill” method that activates dormant HIV so the immune system or the virus kills the cell.
 
Related Coverage: 'Kick and Kill' Technique Targets Dormant HIV Cells
 
If proven effective in humans, antiretroviral therapy may no longer be necessary, according to the release.
 



Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

Cellular proliferation predominantly drives HIV persistence on antiretroviral therapy, according to a new study.
Bijuva (estradiol and progesterone) is the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms due to menopause in women with a uterus.
The switchable CAR T system allows for complete control of the cancer-killing cells, which could improve the treatment’s safety.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$